Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication ...
Last week, the leading developers of treatments for atrial fibrillation (AFib) convened in Boston for the 2026 AF Symposium.
Field Medical announced the presentation of clinical data from the first-in-human study of its FieldForce pulsed field ...
Dr. Yang Yang is an electrophysiologist at the Washington Regional Electrophysiology Clinic, part of the Walker Heart ...
Please provide your email address to receive an email when new articles are posted on . Patients with scar-related ventricular tachycardia (VT) who received VT ablation plus a subcutaneous ICD had ...
Zacks Investment Research on MSN
PLSE shares positive first-in-human nPulse cardiac catheter data
Pulse Biosciences PLSE recently announced late-breaking data from its first-in-human feasibility study of the nPulse Cardiac ...
The first randomized trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular ...
7don MSN
Study finds 90 minutes weekly activity after ablation linked to fewer atrial fibrillation relapses
New research from CU Anschutz scientists suggests that staying physically active after heart rhythm treatment may ...
New research from CU Anschutz scientists suggests that staying physically active after heart rhythm treatment may ...
Johnson & Johnson (NYSE:JNJ) presented pilot-phase data for its OMNYPULSE and VARIPULSE atrial fibrillation platforms at the ...
Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results